Main | December 2005 »

November 29, 2005

Stem cells and chinook

I've now lived in the U.S. of A. for seven years, but had never been north of the border. So I enthusiastically accepted the invitation of the Canadian Stem Cell Network to give a talk on scientific publishing to their trainees (i.e. grad students and postdocs), last Tuesday at their Annual General Meeting in Calgary. The Weather Channel website predicted moderate temperatures around 50oF, but I just couldn't believe it and bundled up in my warmest winter coat. Of course those weathermen were right, and I looked pretty silly in puffy down at 15oC/60oF. Several friendly locals, including the breakfast omelette chef, explained that the balmy temperatures were due to the "chinook" winds blowing from the west across the Rockies. Apparently midwinter chinooks can heat Calgary from deep freeze to balmy in a day, and they last for a few days, too. Lucky Calgarians! Still, I remain awed at the early peoples and pioneers who settled in a prairie where winter temperatures routinely drop to -30oC/-20oF (or so they tell me...)

I'm going way off-topic here...

The Stem Cell Network folks wanted me to explain how to get published in the Nature brand journals. Really, the answer is pretty simple - just tackle a very interesting question, and do fabulous work on it coming to novel and convincing conclusions. Easy, no? So how am I supposed to talk about this for 45 minutes??

Thank goodness, when people like the SCN ask this question, what they really want to know is what happens to their paper once they surrender it to our claws. Do we actually read it ? (YES!) Why don't we peer review all papers? Who are these fearsome anonymous referees, and why do they have to be anonymous anyways? What proportion of submitted papers ends up getting published? Is there any recourse in case of unfair rejections? And so on and so forth - no problem filling that hour. It also gave me a chance to wave the flag for "Action Potential" as our new feedback & discussion forum.

The audience came up with several good questions. The one that stuck with me was about the difficulty in getting negative results published. It can indeed be challenging. Negative results can seem inherently "boring", even if important. And when a negative result contradicts a previously published positive result, it may face a tough battle in review. The best we editors can do is enlist fair reviewers who don't have a personal stake in the controversy, but they may still give the challengers a hard time. The stem cell field certainly has its share of entrenched controversies - for example, is there such a thing as "transdifferentiation" (such as from bone marrow stem cell to neuron)? Or, do adult neural "stem cells" really exist in vivo, or are they an artifact of in vitro culture? The definition of stem-cell-ness is based on in vitro criteria, and sorely overdue for an update. Lots of material here for blogging - chime in!

November 28, 2005

This week's (and last week's) new NN papers

Online since Sunday, November 27th:

Lorenzetti et al., Classical and operant conditioning differentially modify the intrinsic properties of an identified neuron

Voss et al., Sensorimotor attenuation by central motor command signals in the absence of movement

Altier et al., ORL1 receptor–mediated internalization of N-type calcium channels

Aoyama et al., Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse

Online since November 20th, and printed in the December issue:

Jarsky et al., Conditional dendritic spike propagation following distal synaptic activation of hippocampal CA1 pyramidal neurons

Arumugam et al., NMDA receptors regulate developmental gap junction uncoupling via CREB signaling

Laurent et al., The prolactin-releasing peptide antagonizes the opioid system through its receptor GPR10

Liss et al., K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons

Wang et al., Prior experience of rotation is not required for recognizing objects seen from different angles

Apologies...

... to everyone for the thundering silence on "Action Potential" last week. I was out of town, no internet connection at hand, and had neglected to corral any of my colleagues into blogging duties. Sorry! I spent half the week in Calgary at a stem cell conference, which I'll blog a little about later. First, let me get the new NN advance online publication papers up here. Thanks for hanging in there...

November 15, 2005

Publishing in Nature Journals

Following up on interesting things happening at SFN, our chief editor Sandra Aamodt (along with Nature and Nature Reviews Neuroscience editors) gave a talk on Monday on publishing in Nature journals. One of the aims of the talk was to give people a better idea about exactly what happens to a paper once it has been submitted to us. The whole editorial process can sometimes appear to be a bit mysterious, and we are hoping to take away some of the mystery in this talk. Did we succeed? Did you find this talk useful? Feedback welcome!

November 14, 2005

Nature SfN blog, and new meditation research

Two links of interest:

Nature journalist Jim Giles keeps a running diary of SfN here.

The Society for Neuroscience in a press release issued yesterday highlights four posters and slide presentations about meditation research. Guess they like to fan the flames a bit ;-)

Throngs at Dalai Lama SfN lecture

Our chief editor Sandra Aamodt left me a phone message here in the office on Saturday, reporting from the scene in the Convention Center before the DL lecture. Seems she narrowly avoided being squeezed to death by the crowd! Did she manage to get into the hall and hear the talk? Stay tuned...

Also on Saturday, the New York Times ran an op-ed piece by the DL, titled "Our Faith in Science". The link ought to work until Friday Nov 18, but let me excerpt what I think are the main points anyways:

"... the ancient version of cosmology I had been taught... held that the moon was a heavenly body that emitted its own light. But through my telescope the moon was clearly just a barren rock, pocked with craters. If the author of that fourth-century treatise were writing today, I'm sure he would write the chapter on cosmology differently. If science proves some belief of Buddhism wrong, then Buddhism will have to change."

Quite a contrast to the scriptural literalism we hear from so many Christian groups, creationists in particular! Next comes a short discussion of collaborations between Tibetan Buddhist monks and neuroscientists. Richard Davidson's work, as well as studies under way in the labs of Jonathan Cohen and Margaret Kemeny are briefly mentioned. The point is that science and Buddhism can enrich each other - science sets Buddhism straight on cosmology, and may be able some day to explain the neurological mechanisms at work during successful meditation. Buddhism (indeed all religion) can enrich science by contributing an ethical perspective:

"... we must find a way to bring ethical considerations to bear upon the direction of scientific development, especially in the life sciences. By invoking fundamental ethical principles, I am not advocating a fusion of religious ethics and scientific inquiry. Rather, I am speaking of what I call "secular ethics," which embrace the principles we share as human beings: compassion, tolerance, consideration of others, the responsible use of knowledge and power. These principles transcend the barriers between religious believers and non-believers; they belong not to one faith, but to all faiths. ..."

"... It is all too evident that our moral thinking simply has not been able to keep pace with the speed of scientific advancement. Yet the ramifications of this progress are such that it is no longer adequate to say that the choice of what to do with this knowledge should be left in the hands of individuals. This is a point I intend to make when I speak at the annual meeting of the Society for Neuroscience today in Washington. I will suggest that how science relates to wider humanity is no longer of academic interest alone. This question must assume a sense of urgency for all those who are concerned about the fate of human existence."

So far, so good. In fact, there are a good number of serious-minded bioethics efforts under way. In the context of stem cell research and cloning, bioethics also gets a lot of public attention. See the fine American Journal of Bioethics blog for the scoop on all things bioethics. Now what does the DL recommend from the Tibetan Buddhist perspective? Nothing specific in the entire piece, unfortunately! He ends with this sentence:

"Scientists should be more than merely technically adept; they should be mindful of their own motivation and the larger goal of what they do: the betterment of humanity."

Okay... clearly the DL appreciates science and scientific progress. But if, as he suggests, "secular ethics" could take care of the ethical quandaries thrown up by scientific advances, do we need the science/religion dialogue at all?

Four new NN papers online

Here's this week's batch - enjoy! As always, comments are welcome.

Lee at al., "NMDA receptor–independent long-term depression correlates with successful aging in rats"
Kao et al., "Neural correlates of actual and predicted memory formation"
Mante et al., "Independence of luminance and contrast in natural scenes and in the early visual system"
Toyofuku et al., "FARP2 triggers signals for Sema3A-mediated axonal repulsion"

November 11, 2005

Focus on Addiction

Drug use and addiction are pervasive. Addiction has very high overall health costs, once related factors such as heart disease, cancer and accidents are considered. The progression from initial drug use to addiction is influenced by the drug, the user's personality, peer influences and environmental stressors. In our November issue, we present a special focus on addiction, highlighting the biology of some of the most commonly abused substances, exploring the genetics of predisposition to addiction, and examining the components of addictive behavior itself.

Our focus consists of reviews and opinion pieces on this topic as well as a commentary on how the neuroscience of addiction should guide public policy and treatment. Thanks to our sponsors, NIDA and NIAAA, this focus is freely available on-line through January 2006. To access the focus, click here.

Let us know what you think of the focus! Are there some reviews or perspectives you enjoyed more than others? How good are our animal models for addiction? What can be done to improve translation of our knowledge of the basic biology of addiction into effective therapies? We'd love to hear your thoughts on this focus, and on this topic!

The natalizumab enigma

Multiple sclerosis (MS) is a heterogeneous disease that affects primarily young adults and often leads to serious disability. We don't know what causes it, and we cannot cure it. This summer, in our July issue, we editorialized about the tragic crash-and-burn of the promising MS drug natalizumab (marketed as Tysabri(R)). In a nutshell - after passing preliminary clinical trials with flying colors, and being approved by the FDA in an accelerated procedure, natalizumab had to be pulled after just three months because a few patients came down with PML, a devastating, crippling or deadly, infection of brain oligodendrocytes. PML is caused by the JC virus, which most of us get exposed to at some point, without it ever doing any noticable harm. How exactly natalizumab would activate the somnolent JCV is unknown, in large part because we don't know enough about its life cycle and physiology. PML is extremely rare, and mice can't catch it - two facts that unfortunately tend to discourage research.

In response to our editorial, Richard Ransohoff from the Cleveland Clinic wrote us a letter putting forward an interesting hypothesis about the natalizumab - PML link. We had his letter peer-reviewed, and we published it in our October issue. Here's a summary of the idea:

Natalizumab works by interfering with a specific adhesion molecule that the myelin-attacking T cells in MS need to migrate into the brain. The same molecule also functions in cell adhesion in the bone marrow, where blood and immune cells are generated. It is known that natalizumab, as a side effect, leads to release of immature blood cells into the circulation. It has also been suggested that the specific genetic rearrangement that activates dormant JCV occurs in the bone marrow. Therefore natalizumab could lead to release of large numbers of JCV-infected immature cells in JCV carriers, overwhelming the immunosurveillance mechanisms that usually keep JCV in check.

Although we know that about 80% of the population have been exposed to JCV and carry antibodies to it, it is completely unknown how many carry dormant virus that could be activated. And there is no easy reliable test to find out.

Ransohoff's letter has triggered a small flurry of follow-up letters, with authors suggesting their own ideas, or variants on the Ransohoff hypothesis. Now, we can't really publish everyone's favorite thoughts on the subject in the printed pages of the journal - first, not all of them are as original as Ransohoff's, and second - it would never end! The journal is really meant for hard data; we publish hypotheses very, very rarely.

But this discussion itself is very much worth having. If there's any chance at salvaging natalizumab - apparently the most effective treatment for MS that's ever been available - and the entire class of drugs it represents, it will emerge from frank discussion among the experts. So why not have the discussion here, on our blog, on "Action Potential"? We'd be proud and happy to host your "virtual meeting".

November 10, 2005

Slowly taking off...

Seems as though our audience is coming out of the woodwork! Thank you mccm, Gabriel and Thomas for your good wishes, and for leaving email addresses and even website URLs. mccm runs a blog called The Genius, where she/he recently discussed a paper on memory mechanisms published in Nature about a year ago. Gabriel directs us to an upcoming symposium at NYU about imitation behaviors from octopus to man. Very distinguished panelists! Thomas runs BrainEthics, where he welcomes us to the blogosphere with so much enthusiasm that he makes me blush! Thomas, I hope "Action Potential" can live up to your high expectations.

November 09, 2005

Y'all have a great time in Washington!

Yours truly won't be coming to the big neuroscience bash in DC. Boo-hooo!!! The program sounds fabulous. My Nature Neuroscience and Nature colleagues will be giving a talk on how to get published with us, on Monday, Nov 14, at 6:30 pm. We're also going to distribute flyers publicizing this blog, so I hope for lots of new blog participants once everybody is back home with their jet lags slept off.

"Left behind" as I am, I'd love to hear from you conventioneers on this blog. Please leave a comment about whatever you found particularly inspiring, exciting, controversial, ..., at the meeting. I may put those up front as blog entries, and you might spawn some interesting discussions. Also, I'm itching to hear whether the Dalai Lama will give a sensible talk, or whether he'll spout nonsense about brain imaging proving Buddhist "compassion", as Northwestern U.'s Yi Rao fears (read his opinion, and an opposing one, here.)

Have a great trip everyone!

The newest Nature Neuroscience papers

We publish all accepted papers online in the weeks before the print issue comes out. The following papers went online this past Sunday November 6th - a bumper crop.

Dean et al., "Neural population coding of sound level adapts to stimulus statistics"
Egner & Hirsch, "Cognitive control mechanisms resolve conflict through cortical amplification of task-relevant information"
Tavazoie et al., "Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2"
Lafuente & Romo, "Neuronal correlates of subjective sensory experience"
Daw et al., "Uncertainty-based competition between prefrontal and dorsolateral striatal systems for behavioral control"

The floor is open for discussion!

November 07, 2005

"Systems" neuroscience

While typing up the preceding post about our search for a new colleague, it occured to me that "systems neuroscience" sounds a bit foggy - or doesn't it? Here's a definition, cribbed from the MIT Department for Brain and Cognitive Sciences:

"Systems neuroscience follows the pathways of information flow within the central nervous system, attempts to define the kinds of processing occurring there, and uses this information to help explain behavioral functions. Investigators work to understand sensory and perceptual systems and motor control, and how expectations and motivational states influence these basic processes."

Would you agree? Or do you use a different definition?

A job opening at Nature Neuroscience

Come work with us! We're a fun team doing a challenging and very interesting job that involves plenty of scientific discussion, travel to meetings, and now even blogging. One of our colleagues is leaving, and we're looking for someone to step into her shoes. If you are a "systems" neuroscientist with broad scientific curiosity, please take a look at our job ad, and send us an application. Informal enquiries are most welcome, too, to actionpotential@natureny.com.

Some rules to get us started:

We have great hopes for "Action Potential". But it's also an experiment, which may fail. If you've ever participated in an online discussion forum you have probably seen that they can be ruined by "spam" and "trolls". Here are our ground rules (these may change with time):

1. Anything neuroscience, or affecting neuroscience, is fair game. But we will not discuss football leagues, supreme court nominees, or the Tibet question. Grossly off-topic comments will be deleted.

2. We want to strongly encourage you to use your real name, and to provide your email address when commenting. Your name, but not your email address, will appear online with your post. It is possible to comment using an alias, BUT...

3. We will not tolerate any anonymous criticism, be it of us or others, papers in NN or elsewhere. Critical comments are very welcome, but you must sign with your real name and email address. There's a good chance we'll double-check with you via email before putting your strongly critical comment live online. Once more, participants' email addresses remain confidential; you do not need to fear a spam attack when commenting on "Action Potential".

Once again - welcome!!

November 06, 2005

Welcome!

- to our brand-new blog! We're starting this with some trepidation, but hope that we - and you - will soon be comfortable in this online medium. Why a Nature Neuroscience blog? Don't we have enough on our plate already? Trust me, we do...

However, putting together a monthly journal and meeting our readers and authors at conferences, we gradually realized that we ought to offer some sort of simple, easy, low-threshold feedback and dialogue mechanism for our audience. "Action Potential" is going to be it. We'll be posting links to new NN papers as they go online, so you have a chance to comment on them easily. We'll try to stir up discussion about our editorials. We'll offer links to material published elsewhere that we find interesting. We'll blog about exciting findings in neuroscience, science politics, developments in science publishing, etc, etc. Anything neuroscience may show up on the blog, and we'll always invite your comments. We look forward to hearing from you.

Subscribe

Subscribe to this blog's feeds:

[What is this?]